• Hui Liu, Mang Sun, Jing Zhang, Qin Tian, Qing Yu, Yang Liu, Fei Yang, Shangyingying Li, and Shengfen Tu.
• Department of Anesthesiology, Children's Hospital of Chongqing Medical University, Chongqing, China.
• Acta Anaesthesiol Scand. 2019 Aug 1; 63 (7): 847-852.

BackgroundThe intranasal route of dexmedetomidine (DEX) administration is becoming increasingly popular for providing adequate sedation during short examinations in infants and children. However, data on the 90% effective dose (ED90) of intranasal DEX are rare in children under 3 years old.MethodsThis is a double-blind trial using a biased coin design up-and-down sequential method (BCD-UDM). Fifty-three children aged under 3 years old requiring DEX for EEG were included in our study. The first patient received 2.5 μg kg-1 DEX, and the dose of DEX administered to the subsequent patient was determined by the response of the previous patient. The patient responses were recorded and analysed to calculate the ED90 by isotonic regression. The 95% confidence interval (CI) was estimated using a bootstrapping method.ResultsFifty-three patients were included in our study, of which 45 patients were successfully sedated, and the 8 instances of failed sedation were rescued using sevoflurane inhalation, allowing the completion of the procedure. The 90% effective dose of DEX was calculated to be 3.28 µg kg-1 , and the 95% CI was 2.74 ~ 3.39 µg kg-1 . No significant adverse events occurred in any of the patients.ConclusionThe 90% effective dose of intranasal DEX sedation for EEG was 3.28 μg kg-1 in children under 3 years old.© 2019 The Acta Anaesthesiologica Scandinavica Foundation. Published by John Wiley & Sons Ltd.

21 keywords...

hide…